Browsing by Author "Li, Kuncheng"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Retrospective assessment of at-risk myocardium in reperfused acute myocardial infarction patients using contrast‐enhanced balanced steady‐state free‐precession cardiovascular magnetic resonance at 3T with SPECT validation
    (Elsevier, 2021-03-15) Sun, Zheng; Zhang, Qiuhang; Zhao, Huan; Yan, Chengxi; Yang, Hsin‑Jung; Li, Debiao; Li, Kuncheng; Liu, Zhi; Yang, Qi; Dharmakumar, Rohan; Medicine, School of Medicine
    Background: Contrast-enhanced (CE) steady-state free precession (SSFP) CMR at 1.5T has been shown to be a valuable alternative to T2-based methods for the detection and quantifications of area-at-risk (AAR) in acute myocardial infarction (AMI) patients. However, CE-SSFP's capacity for assessment of AAR at 3T has not been investigated. We examined the clinical utility of CE-SSFP and T2-STIR for the retrospective assessment of AAR at 3T with single-photon-emission-computed tomography (SPECT) validation. Materials and methods: A total of 60 AMI patients (ST-elevation AMI, n = 44; non-ST-elevation AMI, n = 16) were recruited into the CMR study between 3 and 7 days post revascularization. All patients underwent T2-STIR, CE-bSSFP and late-gadolinium-enhancement CMR. For validation, SPECT images were acquired in a subgroup of patients (n = 30). Results: In 53 of 60 patients (88 %), T2-STIR was of diagnostic quality compared with 54 of 60 (90 %) with CE-SSFP. In a head-to-head per-slice comparison (n = 365), there was no difference in AAR quantified using T2-STIR and CE-SSFP (R2 = 0.92, p < 0.001; bias:-0.4 ± 0.8 cm2, p = 0.46). On a per-patient basis, there was good agreement between CE-SSFP (n = 29) and SPECT (R2 = 0.86, p < 0.001; bias: - 1.3 ± 7.8 %LV, p = 0.39) for AAR determination. T2-STIR also showed good agreement with SPECT for AAR measurement (R2 = 0.81, p < 0.001, bias: 0.5 ± 11.1 %LV, p = 0.81). There was also a strong agreement between CE-SSFP and T2-STIR with respect to the assessment of AAR on per-patient analysis (R2 = 0.84, p < 0.001, bias: - 2.1 ± 10.1 %LV, p = 0.31). Conclusions: At 3T, both CE-SSFP and T2-STIR can retrospectively quantify the at-risk myocardium with high accuracy.
  • Thumbnail Image
    Item
    The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
    (Alzheimer’s Association, 2021-12-31) Weber, Christopher J.; Carrillo, Maria C.; Jagust, William; Jack, Clifford R., Jr.; Shaw, Leslie M.; Trojanowski, John Q.; Saykin, Andrew J.; Beckett, Laurel A.; Sur, Cyrille; Rao, Naren P.; Mendez, Patricio Chrem; Black, Sandra E.; Li, Kuncheng; Iwatsubo, Takeshi; Chang, Chiung-Chih; Sosa, Ana Luisa; Rowe, Christopher C.; Perrin, Richard J.; Morris, John C.; Healan, Amanda M.B.; Hall, Stephen E.; Weiner, Michael W.; Radiology and Imaging Sciences, School of Medicine
    The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4.